Preferred Stock OfferingsBy Preferred Stock Channel Staff, updated Thu, December 2, 6:56 PM
|This Slide: #127 of 573|
Slide #127. Ovid Therapeutics Inc. — Preferred Stock Offering
Ovid Therapeutics Inc. (NASDAQ:OVID)
Date of Pricing:
Price Per Share:
Preferred Stock Offering Details:
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock ("Series A stock") in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A stock offering (together, the "Offerings") are contingent upon the consummation of the other. The Offerings are subject to market and other conditions, and there can be no assurance as to whether or when the Offerings may be completed, or the actual size or terms of the Offerings. -updated 2/20- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the pricing of underwritten public offerings of (i) 12,500,000 shares of its common stock and (ii) 2,500 shares of its non-voting Series A Convertible Preferred Stock ("Series A stock") (together, the "Offerings"). The public offering price of each share of common stock is $2.00 and the public offering price of each share of Series A stock is $2,000.00. In addition, Ovid Therapeutics has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the number of shares offered in the common stock offering. The Offerings are expected to close on February 22, 2019, subject to customary closing conditions.
Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. Co.'s drug candidates include: OV935, which is being developed in a joint collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies; OV101, which is for the treatment of Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders that are characterized by similar symptoms; and OV329 (GABA aminotransferase inhibitor), which is a preclinical compound being developed by Co. for the treatment of seizures associated with Tuberous Sclerosis Complex and Infantile Spasms.
Open the OVID Page at Preferred Stock Channel »
Free OVID Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Buy (3.20 out of 4)
(ranked lower than approx. 65% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com